DJNJ2 Stock Overview
Researches, develops, manufactures, and sells various products in the healthcare field worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Johnson & Johnson Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$815.00 |
| 52 Week High | US$898.00 |
| 52 Week Low | US$394.50 |
| Beta | 0.53 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 241.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| DJNJ2 | AR Pharmaceuticals | AR Market | |
|---|---|---|---|
| 7D | 0% | -3.4% | 3.1% |
| 1Y | n/a | -27.4% | 132.9% |
Return vs Industry: Insufficient data to determine how DJNJ2 performed against the AR Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DJNJ2 performed against the AR Market.
Price Volatility
| DJNJ2 volatility | |
|---|---|
| DJNJ2 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in AR Market | 8.8% |
| 10% least volatile stocks in AR Market | 4.9% |
Stable Share Price: DJNJ2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DJNJ2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 152,700 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Johnson & Johnson Fundamentals Summary
| DJNJ2 fundamental statistics | |
|---|---|
| Market cap | AR$321.27t |
| Earnings (TTM) | AR$11.49t |
| Revenue (TTM) | AR$81.04t |
28.0x
P/E Ratio4.0x
P/S RatioIs DJNJ2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DJNJ2 income statement (TTM) | |
|---|---|
| Revenue | US$98.66b |
| Cost of Revenue | US$32.01b |
| Gross Profit | US$66.65b |
| Other Expenses | US$52.66b |
| Earnings | US$13.99b |
Last Reported Earnings
Oct 01, 2023
Next Earnings Date
Jan 23, 2024
| Earnings per share (EPS) | 5.81 |
| Gross Margin | 67.56% |
| Net Profit Margin | 14.18% |
| Debt/Equity Ratio | 42.0% |
How did DJNJ2 perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield86%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/23 05:55 |
| End of Day Share Price | 2023/10/26 00:00 |
| Earnings | 2023/10/01 |
| Annual Earnings | 2023/01/01 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Johnson & Johnson is covered by 62 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Charles Butler | Barclays |